Clinical Trial

Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

Study acronym: [18F]PSMA-1007

Recruiting

Summary

Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2024-10-23; most recent amendment 2025-01-16.

Status change: Not Yet Recruiting → Recruiting 2025-01-16

Trial Details

NCT Number	NCT06657131
Lead Sponsor	Heinrich-Heine University, Duesseldorf
Conditions	Prostate Cancer After a Radical Treatment, Biochemical Recurrence of Malignant Neoplasm of Prostate, Biochemical Persistence of Prostate Cancer
Enrollment	250 participants
Start Date	2024-11-01
Primary Completion	2026-11-30 (estimated)
Study Completion	2028-11-30 (estimated)
Updated on ClinicalTrials.gov	2025-01-17